medigraphic.com
ISSN 0185-3325 (Print)
Órgano Oficial del Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz

2015, Number 6

<< Back Next >>

Salud Mental 2015; 38 (6)

Assessment of depressive symptoms in severe smokers with minimal-mild depressive symptomatology receiving pre-smoking abstinence for integrated treatment: a randomized clinical trial

Moreno-Coutiño A, García-Anguiano F, Ruiz-Velasco S, Medina-Mora ME

Language: English
References: 40
Page: 433-439
PDF size: 184.67 Kb.


ABSTRACT

Introduction Smoking and depression have a long-history documented of comorbidity.
Objective The objective of this study was to develop and test a treatment that could simultaneously achieve smoking abstinence and decrease depressive symptoms in a group of heavy smokers with minimal/mild depressive symptomatology.
Method Sixty smokers were randomly assigned to three different treatment settings. Treatment included a pre-abstinence phase, a psychological treatment phase, a pharmacotherapy phase and a follow-up stage. Smokers began the psychological treatment and the pharmacotherapy two weeks before the day they chosen to quit smoking, and monitoring was conducted over a year. Abstinence was confirmed by assessing the levels of urinary cotinine.
Results Using a linear mixed model with individual random effect, baseline data was compared with subsequent assessments; 46% of the patients achieved abstinence. For men, the three treatment settings significantly reduced depressive symptoms and helped smokers to achieve abstinence. For women, only the nicotine patch showed to be effective in the reducing depressive symptoms.
Discussion and conclusion Integral pre-abstinence treatment is effective in aiding smokers to achieve smoking abstinence and improve depressive symptoms.


REFERENCES

  1. Benjet C, Wagner FA, Borges GG, Medina-Mora ME. The relationship of tobacco smoking with depressive symptomatology in the Third Mexican National Addictions Survey. Psychol Med 2004;34(5):881-888.

  2. Lyons M, Hitsman B, Xian H et al. A twin study of smoking, nicotine dependence, and major depression in men. Nicotine Tob Res 2008;10(1):97-108.

  3. Wiesbeck GA, Kuhl HC, Yaldizili O, Wurst FM. Tobacco smoking and depression- results from the WHO/ISBRA study. Neuropsychobiology 2008;57(1-2):26-31.

  4. Glassman A, Covey LS, Stetner F, Rivelli S. Smoking cessation and the course of major depression: A follow-up study. Lancet 2001;357(9272):1929-1932.

  5. Munafò MR, Hitsman B, Rende R, Metcalfe C et al. Effects of progression to cigarette smoking on depressed mood in adolescents: evidence from the National Longitudinal Study of Adolescent Health. Addiction 2008;103(1):162-171.

  6. Mihailescu S, Drucker-Colín R. Nicotine, brain nicotinic receptors, and neuropsychiatric disorders. Arch Med Res 2000;31(2):131-144.

  7. Moreno-Coutiño A, Calderón-Ezquerro C, Drucker-Colín R. Long term changes in sleep and depressive symptoms of smokers in abstinence. Nicotine Tob Res 2007;9(3);389-396.

  8. Lai IC, Hong CJ, Tsai SJ. Association study of nicotinic-receptor variants and major depressive disorder. J Affect Disord 2001;66(1);79-82.

  9. Medina-Mora ME, Borges G, Lara C et al. Prevalencia de trastornos mentales y uso de servicios: resultados de la Encuesta Nacional de Epidemiología Psiquiátrica en México. Salud Ment 2003;26(4);1-16.

  10. Sullivan PF, Kuo PH, Webb BT et al. Genomewide linkage survey of nicotine dependence phenotypes. Drug Alcohol Depend 2008;93(3):210-216.

  11. Cornuz J. Smoking cessation interventions in clinical practice. Eur J Vasc Endovasc Surg 2007;34(4):397-404.

  12. Stead LF, Perera R, Bullen C, Mant D et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2008. Available at: http://onlinelibrary.wiley.com/o/cochrane/clsysrev/articles/ CD000146/frame.html Accessed May 1st 2011.

  13. Wileyto EP, Patterson F, Niaura R et al. Recurrent event analysis of lapse and recovery in a smoking cessation clinical trial using bupropion. Nicotine Tob Res 2005;7(2):257-268.

  14. Etter JF, Stapleton JA. Nicotine replacement therapy for long-term smoking cessation: a meta-analysis. Tob Control 2006;15(4):280-285.

  15. Fiore MC, Thompson SA, Lawrence DL et al. Helping Wisconsin women quit smoking: a successful collaboration. WMJ 2000;99(2):68- 72.

  16. Jorenby DE, Leischow, SJ, Nides MA et al. A controlled trial of sustained- release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999;340(9):685-691.

  17. Rose JE, Behm FM, Westman EC, Kukovich P. Precessation treatment with nicotine skin patch facilitates smoking cessation. Nicotine Tob Res 2006;8(1):89-101.

  18. Schuurmans MM, Diacon AH, van Biljon X, Bolliger CT. Effect of pre-treatment with nicotine patch on withdrawal symptoms and abstinence rates in smokers subsequently quitting with the nicotine patch: a randomized controlled trial. Addiction 2004;99(5):634-640.

  19. Vidrine JI, Cofta-Woerpel L, Daza P, Wright KL et al. Smoking cessation 2: Behavioral treatments. Behav Med 2006;32(3):99-109.

  20. Carroll KM, Rounsaville BJ. Behavioral therapies: The glass would be half full if only we had a glass. In: Miller WR, Carroll KM (eds.). Rethinking substance abuse. What the science shows, and what we should do about it. New York, NY: The Guilford Press; 2006: pp.223-239.

  21. Foulds J, Steinberg MB, Williams JM, Ziedonis DM. Developments in pharmacotherapy for tobacco dependence: past, present and future. Drug Alcohol Rev 2006;25(1):59-71.

  22. Medina-Mora ME, Borges G, Lara C, Benjet C. La salud mental en México y los retos para su atención. Resultados de la Encuesta Nacional de Epidemiología Psiquiátrica. Manual de Trastornos Mentales. Mexico City, Mexico: Asociación Psiquiátrica Mexicana; 2005.

  23. Saxon AJ, Baer JS, Davis TM et al. Smoking cessation treatment among dually diagnosed individuals: Preliminary evaluation of different pharmacotherapy. Nicotine Tob Res 2003;5(4):589-596.

  24. World Health Organization. Composite International Diagnostic Interview. Geneva, Switzerland; 1990.

  25. Heatherton T, Kozlowski L, Frecker R, Fagerström K. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnarie. Br J Addict 1991;86(9):1119-1127.

  26. Jurado S, Villegas ME, Méndez L, Rodríguez F et al. La estandarización del Inventario de Depresión de Beck para los residentes de la Ciudad de México. Salud Ment 1998;21(3):26-31.

  27. Beck CT, Froman RD, Bernal H. Acculturation level and postpartum depression in Hispanic mothers. MCN Am J Matern Child Nurs 2005;30(5):299-304.

  28. Esquivel-Molina CG, Buendía-Cano F, Martínez-García O, Martínez-Mendoza JA et al. Burnout syndrome in medical staff affiliated to a tertiary care hospital. Rev Med Inst Mex Seguro Soc 2007;45(5):427-436.

  29. Lara-Rivas G, Ramírez-Venegas A, Sansores-Martínez R, Espinoza A et al. Indicadores de síntomas de abstinencia en un grupo de fumadores mexicanos. Salud Publica Mex 2007;49:257-262.

  30. James H, Tizabí Y, Taylor R. Rapid method for the simultaneous measurement of nicotine and cotinine in urine and serum by gas chromatography- mass spectrometry. J Chromatogr B, Biomed Sci Appl 1998;708(1-2):87-93.

  31. Cornuz J, Gilbert A, Pinget C et al. Cost-effectiveness of pharmacotherapy for nicotine dependence in primary care settings: a multinational comparison. Tob Control 2006;15(3):152-159.

  32. Okuyemi KS, Ahluwalia JS, Harris KJ. Pharmacoherapy of smoking cessation. Arch Fam Med 2000;9(3):270-281.

  33. Thase ME, Haight BR, Richard N et al. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry 2005;66(8):974-981.

  34. Fiore MC, Jaén, C, Baker T et al. Treating tobacco use and dependence: 2008 Update. Clinical practice guideline. Rockville, MD: U.S. Department of Health and Human Services; 2008.

  35. Hurt RD, Wolter TD, Rigotti N, et al. Bupropion for pharmacologic relapse prevention to smoking: predictors of outcome. Addict Behav 2002;27(4):493-507.

  36. Becker K, Rose J, Albino A. A randomized trial of nicotine replacement therapy in combination with reduced-nicotine cigarettes for smoking cessation. Nicotine Tob Res 2008;10(7):1139-1148.

  37. Díaz-Maroto L, Jiménez-Ruiz C. Tratamiento farmacológico del tabaquismo. Inf Ter Sist Nac Salud 2008;32(3):71-82.

  38. Rovina N, Nikoloutsou I, Katsani G et al. Effectiveness of pharmacotherapy and behavioral interventions for smoking cessation in actual clinical practice. Ther Adv Respir Dis 2009;3(6):279-287.

  39. Smith SS, Jorenby DE, Leischow SJ et al. Targeting smokers at increased risk for relapse: treating women and those with a history of depression. Nicotine Tob Res 2003;5(1):99-109.

  40. Leventhal AM, Waters AJ, Boyd S, Moolchan ET et al. Gender differences in acute tobacco withdrawal: effects on subjective, cognitive, and physiological measures. Exp Clin Psychopharmacol 2007;15(1):21-36.




2020     |     www.medigraphic.com